Tuberculosis, caused by Mycobacterium tuberculosis, is still one of the leading infectious diseases globally. Therefore, novel approaches are needed to face this disease. Efflux pumps are known to contribute to the emergence of M. tuberculosis drug resistance. Thioridazine has shown good anti-TB properties both in vitro and in vivo, likely due to its capacity to inhibit efflux mechanisms. Here we report the design and synthesis of a number of putative efflux inhibitors inspired by the structure of thioridazine. Compounds were evaluated for their in vitro and ex vivo activity against M. tuberculosis H37Rv. Compared to the parent molecule, some of the compounds synthesized showed higher efflux inhibitory capacity, less cytotoxicity, and a remarkable synergistic effect with anti-TB drugs both in vitro and in human macrophages, demonstrating their potential to be used as coadjuvants for the treatment of tuberculosis.
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy / Pieroni, Marco; Machado, Diana; Azzali, Elisa; Santos Costa, Sofia; Couto, Isabel; Costantino, Gabriele; Viveiros, Miguel. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 58:15(2015), pp. 5842-5853. [10.1021/acs.jmedchem.5b00428]
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy
PIERONI, Marco;AZZALI, ELISA;COSTANTINO, Gabriele;
2015-01-01
Abstract
Tuberculosis, caused by Mycobacterium tuberculosis, is still one of the leading infectious diseases globally. Therefore, novel approaches are needed to face this disease. Efflux pumps are known to contribute to the emergence of M. tuberculosis drug resistance. Thioridazine has shown good anti-TB properties both in vitro and in vivo, likely due to its capacity to inhibit efflux mechanisms. Here we report the design and synthesis of a number of putative efflux inhibitors inspired by the structure of thioridazine. Compounds were evaluated for their in vitro and ex vivo activity against M. tuberculosis H37Rv. Compared to the parent molecule, some of the compounds synthesized showed higher efflux inhibitory capacity, less cytotoxicity, and a remarkable synergistic effect with anti-TB drugs both in vitro and in human macrophages, demonstrating their potential to be used as coadjuvants for the treatment of tuberculosis.File | Dimensione | Formato | |
---|---|---|---|
Pieroni J Med Chem.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
957.44 kB
Formato
Adobe PDF
|
957.44 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.